Which patients with metastatic hormone sensitive prostate cancer would you treat with enzalutamide or apalutamide (instead of abiraterone or docetaxel)?  

ENZAMET and TITAN trials published at ASCO 2019 show benefit to both 2nd generation AR antagonists when compared to placebo but wondering how this will change practice given standard of care is abiraterone or docetaxel.



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution